EGFR and cancer: Although previous studies showed that arsenic is a potential drug repurposing agent for NSCLC, other studies showed that long-term exposure to arsenic exerts undesired effects and can lead to cancer progression via the involvement of multiple pathways, including the EGFR signaling[67–70].